ADR Ratio Change

Rhea-AI Summary

Biodexa Pharmaceuticals (Nasdaq: BDRX) announced an ADR ratio change from 1 ADR = 100,000 ordinary shares to 1 ADR = 500,000 ordinary shares, effective on or about April 6, 2026. ADR holders must surrender five old ADRs for one new ADR (New CUSIP: 59564R872).

The change will operate as a one-for-five reverse ADR split for ADRs only; ordinary shares are not affected. The depositary, JP Morgan Chase Bank, N.A., will manage exchanges and sell any aggregate fractional interests, distributing net proceeds. The Company said the change aims to comply with Nasdaq's $1.00 minimum bid requirement but gave no assurance it will achieve that outcome.

Positive

• ADR ratio change could raise per‑ADR price roughly fivefold
• Action aimed to address Nasdaq $1.00 minimum bid noncompliance

Negative

• Company gave no assurance the Ratio Change will achieve Nasdaq compliance
• Mandatory surrender and exchange process may inconvenience ADR holders; fractional proceeds only in cash

Key Figures

Old ADR ratio: 1 ADR : 100,000 ordinary shares New ADR ratio: 1 ADR : 500,000 ordinary shares Exchange ratio: 1 new ADR for every 5 old ADRs +5 more

8 metrics

Old ADR ratio 1 ADR : 100,000 ordinary shares Pre-change ADR structure

New ADR ratio 1 ADR : 500,000 ordinary shares Post-change ADR structure

Exchange ratio 1 new ADR for every 5 old ADRs Mandatory ADR surrender and exchange

Effective date On or about April 6, 2026 Expected ADR ratio change effectiveness

Old CUSIP 59564R880 CUSIP for old ADRs

New CUSIP 59564R872 CUSIP for new ADRs

Nasdaq minimum bid $1.00 per share Stated listing requirement target for ADR price

Current price $0.7684 Before ADR ratio change announcement

Market Reality Check

Price: $0.7684 Vol: Volume 46,864 is at 0.34x...

low vol

$0.7684 Last Close

Volume Volume 46,864 is at 0.34x the 20-day average of 138,403, indicating subdued trading before the ADR change. low

Technical Shares trade well below the 200-day MA of 5.59, with price at 0.7684 and near the 52-week low of 0.7632.

Peers on Argus

BDRX was down 2.38% while close biotech peers showed mixed moves: some down (e.g...

1 Up 1 Down

BDRX was down 2.38% while close biotech peers showed mixed moves: some down (e.g., DRMA, ENTO, SLXN) and some up (e.g., QLGN), suggesting stock-specific factors around the ADR ratio change rather than a unified sector move.

Historical Context

5 past events · Latest: Mar 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 09	Advocacy grant & trial	Positive	+4.9%	Support for FAP patient group and eRapa Phase 3 Fast Track update.
Feb 19	Drug license deal	Positive	+3.2%	License of Phase 1–ready MTX240 molecular glue for GIST from Otsuka.
Feb 04	Exclusive MTX240 license	Positive	-11.0%	Exclusive license of OPB-171775 (MTX240) for GIST and GI oncology pipeline.
Jan 05	CFO board appointment	Positive	+2.0%	Promotion of Fiona Sharp to CFO, Company Secretary, and Board director.
Dec 18	Public offering priced	Negative	-24.0%	Pricing of approximately $10M best efforts public offering with warrants.

Pattern Detected

News has often aligned with price: positive advocacy, licensing, governance changes, and the prior offering all saw price moves consistent with their sentiment, with one notable divergence on a licensing update.

Recent Company History

Over the past few months, Biodexa reported several pipeline and corporate milestones alongside capital markets activity. A December 18, 2025 public offering of approximately $10.0 million preceded a sharp decline. Subsequent governance and pipeline news, including a CFO appointment on January 5, 2026 and multiple MTX240 licensing announcements in February 2026, generally saw positive price reactions. The March 9, 2026 advocacy grant and Phase 3 eRapa update also coincided with a gain. The current ADR ratio change follows this sequence of capital and listing-related steps.

Market Pulse Summary

This announcement details a change in Biodexa’s ADR ratio, effectively a one-for-five reverse ADR sp...

Analysis

This announcement details a change in Biodexa’s ADR ratio, effectively a one-for-five reverse ADR split, intended to help address the Nasdaq $1.00 minimum bid price requirement. The move comes after trading near a 52-week low and well below the 200-day MA. Investors may track how this structural adjustment interacts with recent licensing, advocacy, and prior offering activity, and monitor future filings or pipeline updates as key indicators of trajectory.

Key Terms

american depositary receipts, adr, cusip, nasdaq, +1 more

5 terms

american depositary receipts financial

"announces a ratio change on its American Depositary Receipts (“ADR”) from one (1) ADR"

A certificate traded on U.S. markets that represents ownership of shares in a foreign company, letting U.S. investors buy and sell that company as if it were listed domestically. Think of it as a local voucher for a foreign product: it makes price quotes in dollars, trades on familiar exchanges, and brings differences in liquidity, fees and legal protections that can affect returns and risk compared with buying the underlying foreign shares directly.

adr financial

"ratio change on its American Depositary Receipts (“ADR”) from one (1) ADR representing"

An American Depositary Receipt (ADR) is a financial certificate that lets investors buy shares of a foreign company through U.S. stock markets, similar to buying a local wrapper that represents the underlying foreign shares. ADRs matter because they make investing in overseas companies easier and more liquid by trading in U.S. dollars and under U.S. market rules, while still carrying currency, regulatory, and country-specific risks that can affect share value.

cusip financial

"receive one (1) new ADR (New CUSIP: 59564R872) for every five (5) old ADRs"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

nasdaq financial

"aimed to bring the price of the Company’s ADRs into compliance with the Nasdaq $1.00 minimum"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

minimum bid price financial

"compliance with the Nasdaq $1.00 minimum bid price per share requirement"

The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.

AI-generated analysis. Not financial advice.

March 18, 2026

Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)

ADR Ratio Change

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts (“ADR”) from one (1) ADR representing one hundred thousand (100,000) ordinary shares, to the new ratio of one (1) ADR representing five hundred thousand (500,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be on or about April 6, 2026.

Pursuant to the Ratio Change, ADR holders will be required on a mandatory basis to surrender their ADRs for cancellation and exchange to receive one (1) new ADR (New CUSIP: 59564R872) for every five (5) old ADRs (Old CUSIP: 59564R880). No fractional ADRs will be allocated. The aggregate fractions, if any, will be sold and the net proceeds will be distributed to the entitled ADR holder. The Company's Depositary, JP Morgan Chase Bank, N.A. will contact ADR holders and arrange for the exchange of their existing ADRs for new ADRs.

For ADR holders, the Ratio Change will have the same effect as a one-for-five reverse ADR split. The ordinary shares of Biodexa will not be affected by this change.

The Ratio Change is aimed to bring the price of the Company’s ADRs into compliance with the Nasdaq $1.00 minimum bid price per share requirement, although Biodexa can give no assurance that the Ratio Change will be effective in achieving this goal.

Forward-Looking Statements

Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States.  Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements.

Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements.  These forward-looking statements speak only as of the date of this announcement.  All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above.  Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.
604100717v.1

FAQ

What exactly is the BDRX ADR ratio change effective April 6, 2026?

It changes to one ADR representing 500,000 ordinary shares, a one-for-five reverse ADR split effect. According to Biodexa, holders must surrender five old ADRs to receive one new ADR (New CUSIP 59564R872); ordinary shares remain unchanged.

How will the BDRX ADR exchange process work for current ADR holders?

ADR holders must on a mandatory basis surrender five old ADRs to receive one new ADR. According to Biodexa, JP Morgan Chase Bank, N.A. will contact holders to arrange exchanges and will sell and distribute proceeds for any aggregate fractional interests.

Why is Biodexa (BDRX) changing its ADR ratio on April 6, 2026?

The company aims to increase the ADR share price to meet Nasdaq's $1.00 minimum bid requirement. According to Biodexa, the Ratio Change is intended to bring ADR pricing into compliance but offers no guarantee of success.

Will Biodexa ordinary shares be affected by the BDRX ADR ratio change?

No, ordinary shares will not be affected by the ADR Ratio Change. According to Biodexa, the adjustment applies only to American Depositary Receipts and not to the company's underlying ordinary share capital.

What happens to fractional ADR entitlements after the BDRX ratio change?

No fractional ADRs will be issued; aggregate fractions will be sold and net proceeds distributed to entitled holders. According to Biodexa, holders will receive cash for fractional interests rather than fractional ADRs.

Does the BDRX ADR ratio change guarantee Nasdaq compliance for Biodexa?

No, the Ratio Change does not guarantee Nasdaq compliance with the $1.00 bid rule. According to Biodexa, the action is intended to help achieve compliance but the company provided no assurance it will be effective.